Papers

Selection of our recently published works


  • Vít O. et al. Identification of potential molecular targets for the imaging and treatment of cluster 1 human pheochromocytoma and paraganglioma via comprehensive proteomic characterization. Clinical Proteomics. (2023) 20:39. (here)   

  • Benes J, Kroupova K, Kotrc M, Petrak J, Jarolim P, Novosadova V, Kautzner J, Melenovsky V. FGF-23 is a biomarker of RV dysfunction and congestion in patients with HFrEF. Sci Rep. 2023 Sep 25;13(1):16004. (here) 


  • Soukup J, Kostelanská M, Kereïche S, Hujacová A, Pavelcová M, Petrák J, Kubala Havrdová E, Holada K. Flow Cytometry Analysis of Blood Large Extracellular Vesicles in Patients with Multiple Sclerosis Experiencing Relapse of the Disease. J Clin Med. 2022 May 17;11(10):2832. (here)


  • Vit, O.; Patel, M.; Musil, Z.; Hartmann, I.; Frysak, Z.; Miettinen, M.; Pacak, K.; Petrak, J. Deep Membrane Proteome Profiling Reveals Overexpression of Prostate-Specific Membrane Antigen (PSMA) in High-Risk Human Paraganglioma and Pheochromocytoma, Suggesting New Theranostic Opportunity. Molecules 2021, 26, 6567. (here)

  • Havlenova T, Skaroupkova P, Miklovic M, Behounek M, Chmel M, Jarkovska D, Sviglerova J, Stengl M, Kolar M, Novotny J, Benes J, Cervenka L, Petrak J, Melenovsky V. Right versus left ventricular remodeling in heart failure due to chronic volume overload. Sci Rep. 2021 Aug 24;11(1):17136. doi: 10.1038/s41598-021-96618-8. (here) 

  • Hrdinova T, Toman O, Dresler J, Klimentova J, Salovska B, Pajer P, Bartos O, Polivkova V, Linhartova J, Machova Polakova K, Kabickova H, Brodska B, Krijt M, Zivny J, Vyoral D, Petrak J. Exosomes released by imatinib‑resistant K562 cells contain specific membrane markers, IFITM3, CD146 and CD36 and increase the survival of imatinib‑sensitive cells in the presence of imatinib. Int J Oncol. 2021 Feb;58(2):238-250. doi: 10.3892/ijo.2020.5163. (here)


  • Jankovska E, Lipcseyova D, Svrdlikova M, Pavelcova M, Kubala Havrdova E, Holada K, Petrak J. Quantitative proteomic analysis of cerebrospinal fluid of women newly diagnosed with multiple sclerosis. Int J Neurosci. 2020 Oct 29:1-11. doi: 10.1080/00207454.2020.1837801. (here)  

  • Vit O, Harant K, Klener P, Man P, Petrak J. A three-pronged "Pitchfork" strategy enables an extensive description of the human membrane proteome and the identification of missing proteins. J Proteomics. 2019 Jul 30;204:103411. doi: 10.1016/j.jprot.2019.103411. (here)

  • Jankovska E, Svitek M, Holada K, Petrak J. Affinity depletion versus relative protein enrichment: a side-by-side comparison of two major strategies for increasing human cerebrospinal fluid proteome coverage. Clin Proteom (2019) 16:9 https://doi.org/10.1186/s12014-019-9229-1 (here)
      
  • Petrak J, Havlenova T, Krijt M, Behounek M, Franekova J, Cervenka L, Pluhacek T, Vyoral D, Melenovsky V. Myocardial iron homeostasis and hepcidin expression in a rat model of heart failure at different levels of dietary iron intake. Biochim Biophys Acta Gen Subj. 2019 Apr;1863(4):703-713. doi: 10.1016/j.bbagen.2019.01.010. (here)

  • Melenovsky V, Cervenka L, Viklicky O, Franekova J, Havlenova T, Behounek M, Chmel M, Petrak J. Kidney Response to Heart Failure: Proteomic Analysis of Cardiorenal Syndrome. Kidney Blood Press Res. 2018 Sep 20;43(5):1437-1450. doi: 10.1159/000493657. (here)


  • Krijt M, Jirkovska A, Kabickova T, Melenovsky V, Petrak J, Vyoral D. Detection and quantitation of iron in ferritin, transferrin and labile iron pool (LIP) in cardiomyocytes using 55Fe and storage phosphorimaging. BBA-GEN SUBJECTS 1862 (2018) 2895-2901. https://doi.org/10.1016/j.bbagen.2018.09.005. (here)


  • Melenovsky V, Hlavata K, Sedivy P, Dezortova M, Borlaug BA, Petrak J, Kautzner J, Hajek M. Skeletal Muscle Abnormalities and Iron Deficiency in Chronic Heart Failure. Circ Heart Fail. 2018; 11e004800. doi: 10.1161/CIRCHEARTFAILURE.117.004800. (here)

  • Zimmermannova O, Doktorova E, Stuchly J, Kanderova V, Kuzilkova D, Strnad H,
    Starkova J, Alberich-Jorda M, Falkenburg JHF, Trka J, Petrak J, Zuna J, Zaliova
    M. An activating mutation of GNB1 is associated with resistance to tyrosine
    kinase inhibitors in ETV6-ABL1-positive leukemia. Oncogene. 2017 Oct
    26;36(43):5985-5994. (here)     

  • Vyoral D, Petrak J. Therapeutic potential of hepcidin - the master regulator of iron metabolism. Pharmacol Res. 2017 Jan; 115:242-254 (here)

  • Melenovsky V, Petrak J, Mracek T, Benes J, Borlaug BA, Nuskova H, Pluhacek T, Spatenka J, Kovalcikova J, Drahota Z, Kautzner J, Pirk J, Houstek J. Myocardial iron content and mitochondrial function in human heart failure: a direct tissueanalysis. Eur J Heart Fail. 2017 Apr;19(4):522-530 (here)


  • Vit O, Petrak J. Integral membrane proteins in proteomics. How to break open the black box? J Proteomics. 2017 Feb 5;153:8-20 Review. (here)


  • Sedmera D, Neckar J, Benes J Jr, Pospisilova J, Petrak J, Sedlacek K,Melenovsky V. Changes in Myocardial Composition and Conduction Properties in Rat Heart Failure Model Induced by Chronic Volume Overload. Front Physiol. 2016 Aug 25;7:367. (here)


  • Toman O, Kabickova T, Vit O, Fiser R, Polakova KM, Zach J, Linhartova J,Vyoral D, Petrak J. Proteomic analysis of imatinib-resistant CML-T1 cells reveals calcium homeostasis as a potential therapeutic target. Oncol Rep. 2016 Sep;36(3):1258-68. (here)


  • Vit O, Man P, Kadek A, Hausner J, Sklenar J, Harant K, Novak P, Scigelova M,Woffendin G, Petrak J. Large-scale identification of membrane proteins based onanalysis of trypsin-protected transmembrane segments. J Proteomics. 2016 Oct 21;149:15-22 (here)


  • Lorkova L, Scigelova M, Arrey TN, Vit O, Pospisilova J, Doktorova E, Klanova M, Alam M, Vockova P, Maswabi B, Klener P Jr, Petrak J. Detailed Functional and Proteomic Characterization of Fludarabine Resistance in Mantle Cell Lymphoma Cells. PLoS One. 2015 Aug 18;10(8):e0135314.  (here)


  • Klanova M, Lorkova L, Vit O, Maswabi B, Molinsky J, Pospisilova J, Vockova P, Mavis C, Lateckova L, Kulvait V, Vejmelkova D, Jaksa R, Hernandez F, Trneny M, Vokurka M, Petrak J, Klener P Jr. Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents. Mol Cancer. 2014 Jun 27;13(1):159. (here)